Response assessment to anti-CTLA4 or/and anti-PD1 immunotherapy in mucosal melanomas.

e21517Background: Immune-checkpoint inhibitors improved significantly the outcomes of metastatic cutaneous melanoma. For rare sub-groups such as mucosal melanomas, only few published data are avail...